Scailyte AG

Corporate information

Scailyte is an ETH spin-off based on pioneering research from Manfred Claassen, Professor for Computational Biology at ETH Zurich. The company has developed the first discovery engine that applies artificial intelligence to single-cell data in order to identify cellular biomarkers. It can intelligently crunch hundreds of millions of data points provided by millions of cells from both sick and healthy people in a matter of a few days. The artificial intelligence is trained to identify patterns that point to specific diseases on the cellular level. Scailyte has already successfully identified a signature for the skin cancer Cutaneous T-Cell Lymphoma (CTCL) and patented the biomarker that allows very early diagnosis. The company is now working on turning this finding into a diagnostic test. Furthermore, the discovery of two more biomarkers including an early diagnostic for Endometriosis, a condition that impacts over 170 million women worldwide, is well underway.